The study is evaluating the effect of treatment with ION-682884 compared to placebo for 120 weeks on cardiovascular mortality and recurrent CV clinical events in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) who are receiving standard of care treatment.
Please use this link for further information:
Primary Investigator: Timothy Raymond